• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.“四支柱实践转型计划”提高65岁及以上成年人疫苗接种率的成本效益分析
J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.
2
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.18-64 岁高危成年人疫苗接种率提高的成本效益:基于模型的决策分析。
BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.
3
Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.基于实践的干预措施提高 65 岁以下成年人疫苗接种率的成本效益。
Hum Vaccin Immunother. 2017 Oct 3;13(10):2207-2212. doi: 10.1080/21645515.2017.1356526.
4
Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.肺炎球菌和流感疫苗接种常规程序的成本效益。
Am J Manag Care. 2013 Jan 1;19(1):e30-7.
5
Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.2013年美国四种主要成人疫苗可预防疾病的估计人力和经济负担
J Prim Prev. 2015 Aug;36(4):259-73. doi: 10.1007/s10935-015-0394-3.
6
Pertussis in adolescents and adults: should we vaccinate?青少年和成人中的百日咳:我们应该接种疫苗吗?
Pediatrics. 2005 Jun;115(6):1675-84. doi: 10.1542/peds.2004-2509.
7
Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.对香港长期护理机构老年人进行流感和肺炎球菌疫苗接种的成本效益分析。
J Epidemiol Community Health. 2009 Nov;63(11):906-11. doi: 10.1136/jech.2008.081885. Epub 2009 Jul 15.
8
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.美国老年人肺炎球菌疫苗接种的成本效益以及提高接种率的项目的变化。
J Am Geriatr Soc. 2024 Aug;72(8):2423-2433. doi: 10.1111/jgs.19031. Epub 2024 Jun 1.
9
Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.巴西使用破伤风-白喉-无细胞百日咳(Tdap)疫苗进行普遍孕产妇免疫的成本效益分析。
Vaccine. 2016 Mar 18;34(13):1531-1539. doi: 10.1016/j.vaccine.2016.02.026. Epub 2016 Feb 17.
10
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.13价肺炎球菌结合疫苗(PCV13)在澳大利亚老年人中的成本效益
Vaccine. 2017 Aug 3;35(34):4307-4314. doi: 10.1016/j.vaccine.2017.06.085. Epub 2017 Jul 8.

引用本文的文献

1
A Structured Narrative Literature Review of the Broader Value of Adult Immunisation Programmes.成人免疫规划更广泛价值的结构化叙述性文献综述
Vaccines (Basel). 2024 Jul 29;12(8):852. doi: 10.3390/vaccines12080852.
2
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.开发中的成人剂型肺炎球菌疫苗在老年美国成年人中的成本效益。
Vaccine. 2023 Jul 5;41(30):4431-4437. doi: 10.1016/j.vaccine.2023.06.007. Epub 2023 Jun 12.
3
Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.进一步研究成人肺炎球菌疫苗接种率改善项目是否值得?价值信息分析。
Vaccine. 2021 Jun 16;39(27):3608-3613. doi: 10.1016/j.vaccine.2021.05.037. Epub 2021 May 25.
4
Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries.低收入和中等收入国家成人疫苗可预防疾病的情况评估以及免疫宣传与政策的潜力。
Vaccine. 2021 Mar 12;39(11):1556-1564. doi: 10.1016/j.vaccine.2021.01.066. Epub 2021 Feb 19.
5
Impact of a Catch-Up Strategy of DT-IPV Vaccination during Hospitalization on Vaccination Coverage among People Over 65 Years of Age in France: The HOSPIVAC Study (Vaccination during Hospitalization).法国65岁以上人群住院期间DT-IPV疫苗补种策略对疫苗接种覆盖率的影响:HOSPIVAC研究(住院期间疫苗接种)
Vaccines (Basel). 2020 Jun 9;8(2):292. doi: 10.3390/vaccines8020292.
6
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.美国老年人群中肺炎球菌疫苗接种政策和接种计划的成本效益。
J Am Geriatr Soc. 2020 Jun;68(6):1271-1278. doi: 10.1111/jgs.16373. Epub 2020 Feb 22.
7
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.一项旨在提高高风险 50-64 岁人群中肺炎球菌疫苗接种率的干预措施与扩大基于年龄的推荐意见相比:探索性成本效益分析。
Hum Vaccin Immunother. 2019;15(4):863-872. doi: 10.1080/21645515.2018.1564439. Epub 2019 Feb 20.
8
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.18-64 岁高危成年人疫苗接种率提高的成本效益:基于模型的决策分析。
BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.
9
Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.基于实践的干预措施提高 65 岁以下成年人疫苗接种率的成本效益。
Hum Vaccin Immunother. 2017 Oct 3;13(10):2207-2212. doi: 10.1080/21645515.2017.1356526.

本文引用的文献

1
Using the 4 Pillars Practice Transformation Program to Increase Pneumococcal Immunizations for Older Adults: A Cluster-Randomized Trial.使用四支柱实践转型计划提高老年人肺炎球菌疫苗接种率:一项整群随机试验。
J Am Geriatr Soc. 2017 Jan;65(1):114-122. doi: 10.1111/jgs.14451. Epub 2016 Oct 18.
2
Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.13价肺炎球菌结合疫苗在美国50岁及以上成年人中的增量成本效益
J Gen Intern Med. 2016 Aug;31(8):901-8. doi: 10.1007/s11606-016-3651-0. Epub 2016 Mar 14.
3
The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010.2006 - 2010年美国50岁人群中百日咳的估计发病率。
BMC Infect Dis. 2015 Nov 19;15:534. doi: 10.1186/s12879-015-1269-1.
4
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.多糖结合疫苗预防成人肺炎球菌性肺炎。
N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.
5
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.13 价肺炎球菌结合疫苗在儿童中的使用对美国儿童和成人侵袭性肺炎球菌病的影响:基于多地点、人群的监测分析。
Lancet Infect Dis. 2015 Mar;15(3):301-9. doi: 10.1016/S1473-3099(14)71081-3. Epub 2015 Feb 3.
6
Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season.2013 - 2014年美国流感季接种疫苗避免的流感发病和住院情况估计
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4.
7
United States life tables, 2010.美国生命表,2010年。
Natl Vital Stat Rep. 2014 Nov;63(7):1-63.
8
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.更新成本效益——每质量调整生命年5万美元阈值令人好奇的韧性。
N Engl J Med. 2014 Aug 28;371(9):796-7. doi: 10.1056/NEJMp1405158.
9
Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.美国消除老年人群疫苗接种率差异项目的成本效益
BMC Public Health. 2014 Jul 15;14:718. doi: 10.1186/1471-2458-14-718.
10
Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.评估破伤风白喉无细胞百日咳联合疫苗(Tdap)预防百日咳的效果:免疫迅速衰减的证据以及 Tdap 品牌效力的差异。
J Infect Dis. 2014 Sep 15;210(6):942-53. doi: 10.1093/infdis/jiu322. Epub 2014 Jun 5.

“四支柱实践转型计划”提高65岁及以上成年人疫苗接种率的成本效益分析

Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.

作者信息

Smith Kenneth J, Zimmerman Richard K, Nowalk Mary Patricia, Lin Chyongchiou J

机构信息

Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

Department of Family Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

出版信息

J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.

DOI:10.1111/jgs.14588
PMID:28024090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5397321/
Abstract

OBJECTIVES

To estimate the cost-effectiveness of an intervention to increase pneumococcal, influenza, and pertussis-containing vaccine uptake in adults aged 65 and older in primary care practices.

DESIGN

Markov decision analysis model, comparing the cost-effectiveness of the 4 Pillars Practice Transformation Program with no intervention.

SETTING

Diverse primary care practices in two U.S. cities.

PARTICIPANTS

Clinical trial participants aged 65 and older.

MEASUREMENTS

Quality-adjusted life years (QALYs), public health outcomes, and costs. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial. Other parameters were derived from the medical literature and Centers for Disease Control and Prevention data. All parameters were individually and simultaneously varied over their distributions.

RESULTS

With the intervention program and extrapolating over 10 years, there would be approximately 60,920 fewer influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses in adults aged 65 and older. Total per-person vaccination and illness costs with the intervention were $23.93 higher than without the intervention, with a concurrent increase in effectiveness of 0.0031 QALYs, or $7,635 per QALY gained. In sensitivity analyses, no individual parameter variation caused the intervention to cost more than $50,000 per QALY gained.

CONCLUSIONS

Implementing an intervention based on the 4 Pillars Practice Transformation Program is a cost-effective undertaking in primary care practices for individuals aged 65 and older, with predicted public health benefits.

摘要

目标

评估一项干预措施在基层医疗实践中提高65岁及以上成年人接种含肺炎球菌、流感和百日咳疫苗比例的成本效益。

设计

马尔可夫决策分析模型,比较“四支柱实践转型计划”与无干预措施的成本效益。

地点

美国两个城市的不同基层医疗实践机构。

参与者

65岁及以上的临床试验参与者。

测量指标

质量调整生命年(QALYs)、公共卫生结果和成本。疫苗接种率和干预成本来自一项随机对照整群试验。其他参数来自医学文献和疾病控制与预防中心的数据。所有参数在其分布范围内单独且同时变化。

结果

通过干预计划并推算10年,65岁及以上成年人中流感病例将减少约60,920例,百日咳病例减少2,031例,肺炎球菌疾病减少13,842例。干预组的人均疫苗接种和疾病总成本比无干预组高23.93美元,同时有效性增加0.0031个QALYs,即每获得一个QALY成本为7,635美元。在敏感性分析中,没有单个参数的变化导致干预措施每获得一个QALY的成本超过50,000美元。

结论

在基层医疗实践中对65岁及以上人群实施基于“四支柱实践转型计划”的干预措施具有成本效益,且预计会带来公共卫生效益。